ZE00-0388
/ Mondego Bio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
Efficacy, in vivo safety, and PK/PD studies for novel, oral, highly selective PTPN2/1 inhibitor (ZE00-0388)
(AACR 2026)
- "Solo treatments with ZE00-0388 demonstrated tumor growth inhibition of 81% and in combination with anti-mPD-1 complete regression of tumor in 50% of animals. ZE00-0388 has a very favorable safety profile with tolerated doses significantly above pre-clinical proof-of-concept efficacious doses, which indicates that ZE00-0388 should have a very broad therapeutic window."
PK/PD data • Preclinical • Oncology • IFNG • PTPN2
1 to 1
Of
1
Go to page
1